Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CellaVision AB ( (SE:CEVI) ) is now available.
CellaVision AB has called its Annual General Meeting for 28 April 2026 at the company’s premises in Lund, Sweden, setting out participation procedures for registered and nominee-registered shareholders, as well as rules for proxy representation. The meeting agenda includes standard corporate governance items such as approval of financial statements, discharge of liability for the board and CEO, and resolutions on board composition, remuneration, and auditor appointments.
The Nomination Committee proposes that Anton Walfridsson chair the AGM, that KPMG AB be re-elected as the company’s auditor until 2027, and that existing principles for appointing the Nomination Committee remain in force, while final proposals on board members and board remuneration will be announced ahead of the meeting. The board also proposes a dividend of SEK 2.75 per share for the 2025 financial year, with a planned record date of 30 April 2026, underscoring continued shareholder returns and offering investors visibility on capital distribution pending AGM approval.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK158.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision AB is a Swedish medical technology company specializing in digital morphology solutions for hematology laboratories. Its primary products focus on automated analysis of blood and body fluids, targeting clinical laboratories and hospitals seeking more efficient and standardized diagnostic workflows.
Average Trading Volume: 37,110
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.42B
Find detailed analytics on CEVI stock on TipRanks’ Stock Analysis page.